A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks*, Carin A. T. C. Lunenburg, Femke M. de Man, Didier Meulendijks, Geert W. J. Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentje, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Albert J. ten Tije, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlene H. W. van de Poel, Caroline M. P. W. MandigersHilde Rosing, Jos H. Beijnen, Erik van Werkhoven, Andre B. P. van Kuilenburg, Ron H. N. van Schaik, Ron H. J. Mathijssen, Jesse J. Swen, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Jan H. M. Schellens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)60-67
Number of pages8
JournalEuropean Journal of Cancer
Volume107
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Cost-analysis
  • Dihydropyrimidine dehydrogenase
  • DPYD
  • Pharmacogenetics
  • Fluoropyrimidines
  • Genotyping
  • Toxicity
  • FLUOROURACIL PLUS LEUCOVORIN
  • METASTATIC COLORECTAL-CANCER
  • ORAL CAPECITABINE
  • TOXICITY
  • 5-FLUOROURACIL
  • DEFICIENCY
  • PREDICTOR

Cite this

Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G-J., Baars, A., Dezentje, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W., ... Schellens, J. H. M. (2019). A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 107, 60-67. https://doi.org/10.1016/j.ejca.2018.11.010